<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499368</url>
  </required_header>
  <id_info>
    <org_study_id>LAF-BR-CT-302</org_study_id>
    <nct_id>NCT01499368</nct_id>
  </id_info>
  <brief_title>A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the healing rate and safety of Lafutidine in erosive esophagitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery Rates of Reflux Esophagitis</measure>
    <time_frame>8 weeks</time_frame>
    <description>Recovery rates of reflux esophagitis on the Esophago Gastro Duodenoscopy test after 8 week treatment-FAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Days Without 'Cardinal Symptom'</measure>
    <time_frame>4 or 8 week</time_frame>
    <description>The proportion of days without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sesation in the chest, Acid reflux, Heartburn including chest pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Daytimes Without 'Cardinal Symptom'</measure>
    <time_frame>4 or 8 week</time_frame>
    <description>The proportion of daytimes without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Nighttimes Without 'Cardinal Symptom'</measure>
    <time_frame>4 or 8 week</time_frame>
    <description>The proportion of Nighttimes without 'Cardinal symptom' after 4 or 8 treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">495</enrollment>
  <condition>Erosive Esophagitis</condition>
  <arm_group>
    <arm_group_label>Lafutidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lafutidine 20mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Famotidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Famotidine 40mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omeprazole</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Omeprazole 20mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lafutidine</intervention_name>
    <description>Lafutidine 20mg/day</description>
    <arm_group_label>Lafutidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Famotidine 40mg/day</description>
    <arm_group_label>Famotidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole 20mg/day</description>
    <arm_group_label>Omeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who had symptoms of heartburn with a diagnosis of grade A to D reflux&#xD;
             esophagitis according to the Los Angeles classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastric or duodenal ulcers (excluding ulcer scars)&#xD;
&#xD;
          -  Concurrent presence of Barrett's esophagus&#xD;
&#xD;
          -  A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks&#xD;
&#xD;
          -  Other conditions considered by the attending physician to potentially affect the&#xD;
             assessment of efficacy and safety&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Woo Lee</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <results_first_submitted>January 16, 2018</results_first_submitted>
  <results_first_submitted_qc>August 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
    <mesh_term>Lafutidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lafutidine</title>
          <description>Lafutidine 20mg/day&#xD;
Lafutidine 10mg bid, po</description>
        </group>
        <group group_id="P2">
          <title>Famotidine</title>
          <description>Famotidine 40mg/day&#xD;
Famotidine 20mg bid, po</description>
        </group>
        <group group_id="P3">
          <title>Omeprazole</title>
          <description>Omeprazole 20mg/day&#xD;
Omeprazole 20mg qd(daily), po</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="167"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet I/E criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Concomitant medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Deviation from visit window</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Error of Prescriptions</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Because of a Duplicated subject in Active comparator, One was excluded.</population>
      <group_list>
        <group group_id="B1">
          <title>Lafutidine</title>
          <description>Lafutidine 20mg/day&#xD;
Lafutidine: Lafutidine 20mg/day</description>
        </group>
        <group group_id="B2">
          <title>Famotidine</title>
          <description>Famotidine 40mg/day&#xD;
Famotidine: Famotidine 40mg/day</description>
        </group>
        <group group_id="B3">
          <title>Omeprazole</title>
          <description>Omeprazole 20mg/day&#xD;
Omeprazole: Omeprazole 20mg/day</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="162"/>
            <count group_id="B3" value="167"/>
            <count group_id="B4" value="494"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age, Mean+-STD (years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.20" spread="13.57"/>
                    <measurement group_id="B2" value="51.25" spread="12.76"/>
                    <measurement group_id="B3" value="49.65" spread="13.84"/>
                    <measurement group_id="B4" value="50.36" spread="13.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.00" lower_limit="21.00" upper_limit="73.00"/>
                    <measurement group_id="B2" value="53.00" lower_limit="24.00" upper_limit="74.00"/>
                    <measurement group_id="B3" value="50.00" lower_limit="20.00" upper_limit="74.00"/>
                    <measurement group_id="B4" value="52.00" lower_limit="20.00" upper_limit="74.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>20 years~ 29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 years ~ 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 years ~ 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 years ~ 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 years ~ 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70 years ~ 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recovery Rates of Reflux Esophagitis</title>
        <description>Recovery rates of reflux esophagitis on the Esophago Gastro Duodenoscopy test after 8 week treatment-FAS</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lafutidine</title>
            <description>Lafutidine 20mg/day&#xD;
Lafutidine 10mg bid, po</description>
          </group>
          <group group_id="O2">
            <title>Famotidine</title>
            <description>Famotidine 40mg/day&#xD;
Famotidine 20mg bid, po</description>
          </group>
          <group group_id="O3">
            <title>Omeprazole</title>
            <description>Omeprazole 20mg/day&#xD;
Omeprazole 20mg qd(daily), po</description>
          </group>
        </group_list>
        <measure>
          <title>Recovery Rates of Reflux Esophagitis</title>
          <description>Recovery rates of reflux esophagitis on the Esophago Gastro Duodenoscopy test after 8 week treatment-FAS</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Recovered</title>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not recovered</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority: The Lower limit is not lower than -15%</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Days Without 'Cardinal Symptom'</title>
        <description>The proportion of days without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sesation in the chest, Acid reflux, Heartburn including chest pain</description>
        <time_frame>4 or 8 week</time_frame>
        <population>Missing = Lafutidine(5) , Omeprazole(1)</population>
        <group_list>
          <group group_id="O1">
            <title>Lafutidine</title>
            <description>Lafutidine 20mg/day&#xD;
Lafutidine 10mg bid, po</description>
          </group>
          <group group_id="O2">
            <title>Famotidine</title>
            <description>Famotidine 40mg/day&#xD;
Famotidine 20mg bid, po</description>
          </group>
          <group group_id="O3">
            <title>Omeprazole</title>
            <description>Omeprazole 20mg/day&#xD;
Omeprazole 20mg qd(daily), po</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Days Without 'Cardinal Symptom'</title>
          <description>The proportion of days without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sesation in the chest, Acid reflux, Heartburn including chest pain</description>
          <population>Missing = Lafutidine(5) , Omeprazole(1)</population>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.31"/>
                    <measurement group_id="O2" value="0.56" spread="0.32"/>
                    <measurement group_id="O3" value="0.69" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.27"/>
                    <measurement group_id="O2" value="0.67" spread="0.32"/>
                    <measurement group_id="O3" value="0.82" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8(LOCF)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.27"/>
                    <measurement group_id="O2" value="0.67" spread="0.32"/>
                    <measurement group_id="O3" value="0.82" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-Inferiority</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon rank sum test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Daytimes Without 'Cardinal Symptom'</title>
        <description>The proportion of daytimes without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain</description>
        <time_frame>4 or 8 week</time_frame>
        <population>Missing = Lafutidine(5) , Omeprazole(1)</population>
        <group_list>
          <group group_id="O1">
            <title>Lafutidine</title>
            <description>Lafutidine 20mg/day&#xD;
Lafutidine 10mg bid, po</description>
          </group>
          <group group_id="O2">
            <title>Famotidine</title>
            <description>Famotidine 40mg/day&#xD;
Famotidine 20mg bid, po</description>
          </group>
          <group group_id="O3">
            <title>Omeprazole</title>
            <description>Omeprazole 20mg/day&#xD;
Omeprazole 20mg qd(daily), po</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Daytimes Without 'Cardinal Symptom'</title>
          <description>The proportion of daytimes without 'Cardinal symptom' after 4 or 8 week treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain</description>
          <population>Missing = Lafutidine(5) , Omeprazole(1)</population>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="0.27"/>
                    <measurement group_id="O2" value="0.68" spread="0.29"/>
                    <measurement group_id="O3" value="0.77" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.23"/>
                    <measurement group_id="O2" value="0.76" spread="0.28"/>
                    <measurement group_id="O3" value="0.87" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8(LOCF)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.23"/>
                    <measurement group_id="O2" value="0.76" spread="0.28"/>
                    <measurement group_id="O3" value="0.87" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Nighttimes Without 'Cardinal Symptom'</title>
        <description>The proportion of Nighttimes without 'Cardinal symptom' after 4 or 8 treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain</description>
        <time_frame>4 or 8 week</time_frame>
        <population>Missing = Lafutidine(5) , Omeprazole(1)</population>
        <group_list>
          <group group_id="O1">
            <title>Lafutidine</title>
            <description>Lafutidine 20mg/day&#xD;
Lafutidine 10mg bid, po</description>
          </group>
          <group group_id="O2">
            <title>Famotidine</title>
            <description>Famotidine 40mg/day&#xD;
Famotidine 20mg bid, po</description>
          </group>
          <group group_id="O3">
            <title>Omeprazole</title>
            <description>Omeprazole 20mg/day&#xD;
Omeprazole 20mg qd(daily), po</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Nighttimes Without 'Cardinal Symptom'</title>
          <description>The proportion of Nighttimes without 'Cardinal symptom' after 4 or 8 treatment-FAS 'Cardinal symptom': Burning sensation in the chest, Acid reflux, Heartburn including chest pain</description>
          <population>Missing = Lafutidine(5) , Omeprazole(1)</population>
          <units>proportion of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.27"/>
                    <measurement group_id="O2" value="0.72" spread="0.30"/>
                    <measurement group_id="O3" value="0.82" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.19"/>
                    <measurement group_id="O2" value="0.78" spread="0.29"/>
                    <measurement group_id="O3" value="0.89" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8(LOCF)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="139"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="146"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.19"/>
                    <measurement group_id="O2" value="0.78" spread="0.29"/>
                    <measurement group_id="O3" value="0.89" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 week, 8 week and 9 week</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lafutidine</title>
          <description>Lafutidine 20mg/day&#xD;
Lafutidine 10mg bid, po</description>
        </group>
        <group group_id="E2">
          <title>Famotidine</title>
          <description>Famotidine 40mg/day&#xD;
Famotidine 20mg bid, po</description>
        </group>
        <group group_id="E3">
          <title>Omeprazole</title>
          <description>Omeprazole 20mg/day&#xD;
Omeprazole 20mg qd(daily), po</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <description>He had musculoskeletal pain because of a car accident, during the treatment period.&#xD;
The physician confirmed that this shoulder pain was caused by muscle tears, which he originally had, and judged that causality of this event with IP was unlikely.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>During the treatment period, he got biopsy at the Dermatology for skin lesion on the left inguinal area, which he had 2 years ago.&#xD;
The result was basal cell carcinoma, but the physician judged that causality of this event with the IP was unlikely.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <description>Pregnancy After 1 month of the treatment peroid, she dropped out of the trial. About 7 months later, she gave birth to a healthy baby boy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Breath odour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="165"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Acute pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Mixed incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Oropharyngeal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager of Clinical Research</name_or_title>
      <organization>Boryung Pharmaceuticals</organization>
      <phone>+82-2-708-8069</phone>
      <email>rainbowleo@boryung.co.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

